EGRX - Eagle Pharmaceuticals Stock Price, News & Analysis

$56.83 -0.12 (-0.21 %)
(As of 11/23/2017 08:01 AM ET)
Previous Close$56.95
Today's Range$56.20 - $57.50
52-Week Range$45.05 - $97.15
Volume228,200 shs
Average Volume344,116 shs
Market Capitalization$849.79 million
P/E Ratio8.98
Dividend YieldN/A
Beta1.23

About Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.


Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A

Debt

Debt-to-Equity Ratio0.26%
Current Ratio5.30%
Quick Ratio5.15%

Price-To-Earnings

Trailing P/E Ratio8.98
Forward P/E Ratio25.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$189.48 million
Price / Sales4.47
Cash Flow$5.37 per share
Price / Cash10.59
Book Value$11.47 per share
Price / Book4.95

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$6.20
Net Income$81.45 million
Net Margins36.95%
Return on Equity62.60%
Return on Assets44.24%

Miscellaneous

Employees77
Outstanding Shares14,920,000

Frequently Asked Questions for Eagle Pharmaceuticals (NASDAQ:EGRX)

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals announced that its board has authorized a share repurchase program on Thursday, August 10th 2017, which permits the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 13.3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board of directors believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings results on Tuesday, August, 9th. The specialty pharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.71 by $0.09. The specialty pharmaceutical company had revenue of $40.90 million for the quarter, compared to analyst estimates of $43.55 million. Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. Eagle Pharmaceuticals's revenue was up 581.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.53) earnings per share. View Eagle Pharmaceuticals' Earnings History.

Where is Eagle Pharmaceuticals' stock going? Where will Eagle Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued 1-year price objectives for Eagle Pharmaceuticals' stock. Their predictions range from $37.00 to $75.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $62.33 in the next year. View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

  • 1. Mizuho analysts commented, "We view both these programs as zeroes. On the call, mgmt. highlighted its balance sheet flexibility and we continue to believe that the company needs to buy its way out of its current pipeline predicament, ahead of Treanda generics in 2019 (and expect capitulation on further Ryanodex development only after this deal is announced). We summarize 3Q:17 performance in Exhibit 1. We will update our valuation after further digesting call details." (11/8/2017)
  • 2. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/31/2017)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:

  • Michael Graves, Independent Chairman of the Board (Age 54)
  • Scott L. Tarriff, Chief Executive Officer, Independent Director (Age 57)
  • Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer (Age 47)
  • David E. Riggs, Chief Financial Officer (Age 65)
  • Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer (Age 57)
  • Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer (Age 55)
  • Douglas L. Braunstein, Independent Director (Age 56)
  • Richard A. Edlin, Independent Director (Age 56)
  • Sander A. Flaum, Independent Director (Age 80)
  • Robert L. Glenning, Independent Director (Age 56)

Who owns Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.11%), Victory Capital Management Inc. (6.45%), Iridian Asset Management LLC CT (5.37%), First Eagle Investment Management LLC (3.97%), Old Mutual Global Investors UK Ltd. (2.55%) and Prudential Financial Inc. (1.46%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Who sold Eagle Pharmaceuticals stock? Who is selling Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Janus Henderson Group PLC, Allianz Asset Management GmbH, GSA Capital Partners LLP, First Trust Advisors LP, Essex Investment Management Co. LLC, New York State Teachers Retirement System and Alpine Woods Capital Investors LLC. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Proquest Investments Iv, LP, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Insider Buying and Selling for Eagle Pharmaceuticals.

Who bought Eagle Pharmaceuticals stock? Who is buying Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Prudential Financial Inc., Iridian Asset Management LLC CT, Royce & Associates LP, Pictet Asset Management Ltd., Systematic Financial Management LP, Schwab Charles Investment Management Inc. and Granite Investment Partners LLC. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy Eagle Pharmaceuticals stock?

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $56.83.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $849.79 million and generates $189.48 million in revenue each year. The specialty pharmaceutical company earns $81.45 million in net income (profit) each year or $6.20 on an earnings per share basis. Eagle Pharmaceuticals employs 77 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Eagle Pharmaceuticals (NASDAQ:EGRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $62.33 (9.68% upside)

Consensus Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)

Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)

Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Royal Bank Of CanadaReiterated RatingOutperform -> Outperform$81.00 -> $75.00N/AView Rating Details
11/8/2017MizuhoReiterated RatingSell$37.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$75.00N/AView Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 -> $97.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Eagle Pharmaceuticals (NASDAQ:EGRX)

Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Earnings History by Quarter for Eagle Pharmaceuticals (NASDAQ EGRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017$0.51$0.33$52.52 million$50.10 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.44$1.42$70.10 million$76.80 millionViewListenView Earnings Details
3/1/2017Q416$2.24$3.52$86.13 million$81.10 millionViewListenView Earnings Details
11/9/2016Q316$0.71$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.53$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.59)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.56$1.31$3.41 million$36.30 millionViewListenView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.90 million$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.39)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
2017 EPS Consensus Estimate: $3.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$1.46$1.46$1.46
Q2 20171$0.59$0.59$0.59
Q3 20171$0.64$0.64$0.64
Q4 20171$1.01$1.01$1.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eagle Pharmaceuticals (NASDAQ EGRX)

Insider Ownership Percentage: 19.50%
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ EGRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Pete A MeyersCFOBuy350$55.45$19,407.50View SEC Filing  
8/9/2017Douglas L BraunsteinDirectorBuy20,400$49.07$1,001,028.00View SEC Filing  
6/12/2017Pete A MeyersCFOBuy350$71.49$25,021.50View SEC Filing  
5/19/2017David PernockInsiderBuy255$79.69$20,320.95View SEC Filing  
5/16/2017David PernockInsiderBuy200$82.24$16,448.00View SEC Filing  
4/25/2017Proquest Investments Iv, L.P.Major ShareholderSell54,180$88.38$4,788,428.40View SEC Filing  
4/3/2017Proquest Investments Iv, L.P.Major ShareholderSell91,332$83.09$7,588,775.88View SEC Filing  
3/29/2017Proquest Investments Iv, L.P.Major ShareholderSell106,468$83.01$8,837,908.68View SEC Filing  
3/28/2017Proquest Investments Iv, L.P.Major ShareholderSell6,182$83.02$513,229.64View SEC Filing  
3/27/2017Proquest Investments Iv, L.P.Major ShareholderSell39,431$83.00$3,272,773.00View SEC Filing  
3/23/2017Proquest Investments Iv, L.P.Major ShareholderSell1,200$83.05$99,660.00View SEC Filing  
3/23/2017Steven L KrillEVPSell14,125$81.07$1,145,113.75View SEC Filing  
3/22/2017Richard A EdlinDirectorBuy6,000$79.44$476,640.00View SEC Filing  
3/21/2017David PernockInsiderBuy61$83.98$5,122.78View SEC Filing  
3/20/2017Proquest Investments Iv, L.P.Major ShareholderSell100,000$82.06$8,206,000.00View SEC Filing  
3/9/2017David PernockInsiderBuy450$77.84$35,028.00View SEC Filing  
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.00View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.00View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eagle Pharmaceuticals (NASDAQ EGRX)

Source:
DateHeadline
Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare ConferenceEagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 20 at 7:03 PM
Barron’s After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals PlungesBarron’s After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges
www.barrons.com - November 18 at 2:56 AM
Barrons After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals PlungesBarron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges
finance.yahoo.com - November 17 at 12:38 PM
FY2018 EPS Estimates for Eagle Pharmaceuticals, Inc. (EGRX) Raised by AnalystFY2018 EPS Estimates for Eagle Pharmaceuticals, Inc. (EGRX) Raised by Analyst
www.americanbankingnews.com - November 13 at 8:58 AM
Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017
finance.yahoo.com - November 10 at 7:09 PM
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017
finance.yahoo.com - November 10 at 11:48 AM
Eagle Pharmaceuticals, Inc. to Host Earnings CallEagle Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 1:43 AM
Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 ResultsEagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results
finance.yahoo.com - November 9 at 1:43 AM
Eagle Pharmaceuticals posts 3Q profitEagle Pharmaceuticals posts 3Q profit
finance.yahoo.com - November 9 at 1:43 AM
Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 1:43 AM
Mizuho Reiterates Sell Rating for Eagle Pharmaceuticals, Inc. (EGRX)Mizuho Reiterates Sell Rating for Eagle Pharmaceuticals, Inc. (EGRX)
www.americanbankingnews.com - November 8 at 5:08 PM
Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare ConferenceEagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 8 at 5:47 AM
Eagle Pharmaceuticals, Inc. (EGRX) Receives Average Recommendation of "Hold" from AnalystsEagle Pharmaceuticals, Inc. (EGRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 2 at 2:33 PM
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 - Business Wire (press release)Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 - Business Wire (press release)
www.businesswire.com - October 30 at 6:54 PM
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - October 30 at 6:54 PM
FDA To Rule On Elagolix In Q2, More Light From CELGs RADIANCE, TGTX On Watch - NasdaqFDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch - Nasdaq
www.nasdaq.com - October 30 at 3:31 AM
Eagle Pharmaceuticals (EGRX) Announces Tentative FDA Approval ... - StreetInsider.comEagle Pharmaceuticals (EGRX) Announces Tentative FDA Approval ... - StreetInsider.com
www.streetinsider.com - October 28 at 1:26 AM
Eagle Pharma gets tentative FDA approval for Lillys Alimta versionEagle Pharma gets tentative FDA approval for Lilly's Alimta version
finance.yahoo.com - October 27 at 8:23 PM
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute - Business Wire (press release)Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute - Business Wire (press release)
www.businesswire.com - October 27 at 3:20 PM
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-DiluteEagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute
finance.yahoo.com - October 27 at 3:20 PM
FDA tentatively approves Eagle Pharmas cancer drugFDA tentatively approves Eagle Pharma's cancer drug
finance.yahoo.com - October 27 at 3:20 PM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017
finance.yahoo.com - October 24 at 9:22 PM
Q3 2017 EPS Estimates for Eagle Pharmaceuticals, Inc. Cut by Analyst (EGRX)Q3 2017 EPS Estimates for Eagle Pharmaceuticals, Inc. Cut by Analyst (EGRX)
www.americanbankingnews.com - October 19 at 7:54 AM
Brokers Issue Forecasts for Eagle Pharmaceuticals, Inc.s Q4 2017 Earnings (EGRX)Brokers Issue Forecasts for Eagle Pharmaceuticals, Inc.'s Q4 2017 Earnings (EGRX)
www.americanbankingnews.com - October 18 at 11:20 AM
Eagle Pharmaceuticals (EGRX) Reports New Patent for RYANODEX - StreetInsider.comEagle Pharmaceuticals (EGRX) Reports New Patent for RYANODEX - StreetInsider.com
www.streetinsider.com - October 17 at 11:59 PM
Eagle Pharmaceuticals Announces New Patent for RYANODEXEagle Pharmaceuticals Announces New Patent for RYANODEX
finance.yahoo.com - October 17 at 6:58 PM
Eagle Pharmaceuticals is Now Oversold - NasdaqEagle Pharmaceuticals is Now Oversold - Nasdaq
www.nasdaq.com - October 16 at 9:23 PM
3 Biotech Values in a Fully Valued Market3 Biotech Values in a Fully Valued Market
finance.yahoo.com - October 15 at 5:30 PM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:46 PM
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017
finance.yahoo.com - October 11 at 7:46 PM
Contrasting Eagle Pharmaceuticals (EGRX) & The CompetitionContrasting Eagle Pharmaceuticals (EGRX) & The Competition
www.americanbankingnews.com - October 9 at 10:24 PM
Eagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of "Hold" from BrokeragesEagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 8 at 10:44 AM
Reviewing Supernus Pharmaceuticals (SUPN) & Eagle Pharmaceuticals (EGRX)Reviewing Supernus Pharmaceuticals (SUPN) & Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - October 6 at 6:24 AM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 10:58 AM
Analyzing Eagle Pharmaceuticals (EGRX) and Its CompetitorsAnalyzing Eagle Pharmaceuticals (EGRX) and Its Competitors
www.americanbankingnews.com - September 28 at 8:30 PM
Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 11:26 AM
Eagle Pharmaceuticals (EGRX) versus Its Rivals Head-To-Head SurveyEagle Pharmaceuticals (EGRX) versus Its Rivals Head-To-Head Survey
www.americanbankingnews.com - September 24 at 8:10 PM
Daily Technical Summary Reports on Generic Drugs Stocks ... - PR Newswire (press release)Daily Technical Summary Reports on Generic Drugs Stocks ... - PR Newswire (press release)
www.prnewswire.com - September 22 at 8:38 AM
Corporate News Blog - Eagle Pharma’s Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection ProductsCorporate News Blog - Eagle Pharma’s Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products
finance.yahoo.com - September 22 at 8:38 AM
Eagle Pharmaceuticals (EGRX) Reports Agreement to License Japanese Rights for Bendamustine Hydrochlorid - StreetInsider.comEagle Pharmaceuticals (EGRX) Reports Agreement to License Japanese Rights for Bendamustine Hydrochlorid - StreetInsider.com
www.streetinsider.com - September 20 at 7:07 PM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017
finance.yahoo.com - September 20 at 4:13 AM
Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : September 19, 2017Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : September 19, 2017
finance.yahoo.com - September 19 at 11:09 PM
Financial Comparison: Eagle Pharmaceuticals (EGRX) versus TherapeuticsMD (TXMD)Financial Comparison: Eagle Pharmaceuticals (EGRX) versus TherapeuticsMD (TXMD)
www.americanbankingnews.com - September 19 at 6:30 AM
Head-To-Head Analysis: Eagle Pharmaceuticals (EGRX) & AbbVie (ABBV)Head-To-Head Analysis: Eagle Pharmaceuticals (EGRX) & AbbVie (ABBV)
www.americanbankingnews.com - September 19 at 2:20 AM
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017
finance.yahoo.com - September 18 at 6:04 PM
Eagle Pharmaceuticals (EGRX) and Its Competitors Financial ReviewEagle Pharmaceuticals (EGRX) and Its Competitors Financial Review
www.americanbankingnews.com - September 18 at 2:30 PM
Eagle Pharmaceuticals (EGRX) vs. Its Competitors Head-To-Head ComparisonEagle Pharmaceuticals (EGRX) vs. Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - September 17 at 6:16 AM
Reviewing Eagle Pharmaceuticals (EGRX) & Aimmune Therapeutics (AIMT)Reviewing Eagle Pharmaceuticals (EGRX) & Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - September 16 at 6:14 AM
Contrasting Eagle Pharmaceuticals (EGRX) and AbbVie (ABBV)Contrasting Eagle Pharmaceuticals (EGRX) and AbbVie (ABBV)
www.americanbankingnews.com - September 15 at 12:36 PM
Reviewing Eagle Pharmaceuticals (EGRX) and The CompetitionReviewing Eagle Pharmaceuticals (EGRX) and The Competition
www.americanbankingnews.com - September 14 at 2:22 AM

Social Media

Financials

Chart

Eagle Pharmaceuticals (NASDAQ EGRX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.